JP7828333B2 - リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法 - Google Patents
リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法Info
- Publication number
- JP7828333B2 JP7828333B2 JP2023516476A JP2023516476A JP7828333B2 JP 7828333 B2 JP7828333 B2 JP 7828333B2 JP 2023516476 A JP2023516476 A JP 2023516476A JP 2023516476 A JP2023516476 A JP 2023516476A JP 7828333 B2 JP7828333 B2 JP 7828333B2
- Authority
- JP
- Japan
- Prior art keywords
- dosing
- day
- days
- week
- medication
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078844P | 2020-09-15 | 2020-09-15 | |
| US63/078,844 | 2020-09-15 | ||
| PCT/JP2021/033855 WO2022059692A1 (en) | 2020-09-15 | 2021-09-15 | Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023541432A JP2023541432A (ja) | 2023-10-02 |
| JP2023541432A5 JP2023541432A5 (https=) | 2024-08-14 |
| JPWO2022059692A5 JPWO2022059692A5 (https=) | 2024-08-14 |
| JP7828333B2 true JP7828333B2 (ja) | 2026-03-11 |
Family
ID=80776678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516476A Active JP7828333B2 (ja) | 2020-09-15 | 2021-09-15 | リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230390251A1 (https=) |
| EP (1) | EP4213842B1 (https=) |
| JP (1) | JP7828333B2 (https=) |
| KR (1) | KR20230067647A (https=) |
| AU (1) | AU2021345171A1 (https=) |
| TW (1) | TW202227060A (https=) |
| WO (1) | WO2022059692A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130005678A1 (en) | 2010-03-30 | 2013-01-03 | Clavis Pharma Asa | Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate |
| WO2019107386A1 (ja) | 2017-11-29 | 2019-06-06 | 大鵬薬品工業株式会社 | 抗腫瘍剤 |
| US20200157066A1 (en) | 2016-05-31 | 2020-05-21 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide Compound or Salt Thereof |
-
2021
- 2021-09-15 AU AU2021345171A patent/AU2021345171A1/en active Pending
- 2021-09-15 KR KR1020237012413A patent/KR20230067647A/ko active Pending
- 2021-09-15 JP JP2023516476A patent/JP7828333B2/ja active Active
- 2021-09-15 EP EP21869378.6A patent/EP4213842B1/en active Active
- 2021-09-15 TW TW110134368A patent/TW202227060A/zh unknown
- 2021-09-15 US US18/026,515 patent/US20230390251A1/en active Pending
- 2021-09-15 WO PCT/JP2021/033855 patent/WO2022059692A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130005678A1 (en) | 2010-03-30 | 2013-01-03 | Clavis Pharma Asa | Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate |
| US20200157066A1 (en) | 2016-05-31 | 2020-05-21 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide Compound or Salt Thereof |
| WO2019107386A1 (ja) | 2017-11-29 | 2019-06-06 | 大鵬薬品工業株式会社 | 抗腫瘍剤 |
Non-Patent Citations (4)
| Title |
|---|
| Clinical Cancer Research，2003年，Vol.9，p.4092-4100 |
| Japanese Journal of Drug Informatics，2010年，Vol.11, No.4，p.217-222 |
| List of 28 Leukemia Chemotherapy Regimen Adopted, [online]，2018年08月21日，INTERNETARCHIVE waybackmachine, [retrieved on 2021.11.12], URL, https://www.saiseikai-hp.chuo.fukuoka.jp/cancer/pdf/rejimen/28.pdf |
| Oncotarget，2016年，Vol.7, No.39，p.63003-63019 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4213842A4 (en) | 2024-07-17 |
| JP2023541432A (ja) | 2023-10-02 |
| AU2021345171A9 (en) | 2024-02-08 |
| AU2021345171A1 (en) | 2023-05-25 |
| US20230390251A1 (en) | 2023-12-07 |
| EP4213842A1 (en) | 2023-07-26 |
| TW202227060A (zh) | 2022-07-16 |
| WO2022059692A1 (en) | 2022-03-24 |
| KR20230067647A (ko) | 2023-05-16 |
| EP4213842B1 (en) | 2026-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7828333B2 (ja) | リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法 | |
| CN113038953B (zh) | 用于治疗癌症的包括krasg12c抑制剂和一种或多种其他药学活性药剂的组合疗法 | |
| WO2022059691A1 (en) | Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor | |
| US20240238300A1 (en) | Treatment methods for subjects with cancer having an aberration in egfr and/or her2 | |
| AU2022355189B2 (en) | Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator | |
| WO2025006697A1 (en) | Treatment methods for subjects with non-small cell lung cancer having an aberration in egfr | |
| RU2848459C1 (ru) | Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы | |
| RU2859365C2 (ru) | Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы | |
| TWI914404B (zh) | 利用核糖核苷酸還原酶抑制劑治療核糖核苷酸還原酶相關疾病之方法 | |
| US20240408100A1 (en) | Treatment methods for subjects having cancer with a dysregulated mapk and/or pi3k pathway | |
| HK40129790A (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| HK40055650A (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240805 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240805 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250826 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251027 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260203 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260227 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7828333 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |